Clinical implications of converting stable haemodialysis patients from subcutaneous to intravenous administration of darbepoetin alfa.

Background: The erythropoiesis-stimulating protein darbepoetin alfa (Aranesp) can be given intravenously (i.v.) or subcutaneously (s.